Neurology

EarliTec Diagnostics, Inc. Raises $21.5 Million in Series B Financing; Funds to Accelerate Commercialization of EarliPoint Evaluation and Further Product Development

Retrieved on: 
Tuesday, April 2, 2024
Neurology, Biometrics, Health, Mental Health, Medical Devices, Children, Health Technology, Consumer, Nexus, Diagnosis, Professor, Ageing, Child, Hope, CDC, Spectrum, Multimedia

The funds will be used to expand commercialization efforts and advance clinical research for the first-in-kind EarliPoint™ Evaluation (“EarliPoint”), which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.

Key Points: 
  • The funds will be used to expand commercialization efforts and advance clinical research for the first-in-kind EarliPoint™ Evaluation (“EarliPoint”), which aids clinicians in the diagnosis and assessment of autism in children aged 16-to-30 months.
  • EarliPoint is the first personalized, quantifiable, and objective tool for children aged 16 months to 30 months suspected of having autism.
  • "EarliPoint represents a meaningful step forward in better, accessible care for autistic children.
  • "We are excited to partner with providers across the nation to deliver EarliPoint.

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
Tuesday, April 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.

Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders

Retrieved on: 
Wednesday, April 3, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Schizophrenia, Drug discovery, Patient, DSM-IV codes, Safety, Therapy, Allosteric regulation, Pharmaceutical industry

Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.

Key Points: 
  • Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.
  • The platform has a track record of identifying highly selective, brain penetrant small molecule drugs, a class that has the potential to revolutionize the treatment of neurological disorders.
  • Neurosterix’s lead program is a muscarinic acetylcholine receptor subtype 4 positive allosteric modulator (“M4 PAM”) for the treatment of patients suffering from schizophrenia.
  • However, Neurosterix will accelerate its pursuit of these exciting medicines through acquiring Addex’s industry-leading proprietary high-throughput allosteric modulator drug discovery platform and a portfolio of preclinical neuroscience assets.

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Retrieved on: 
Tuesday, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, AbbVie, Prader–Willi syndrome, Scripps Research, IGM, Horizon, Delusion, Executive, Harvey Mudd College, Patient, Acquisition, Rett syndrome, Doctor of Philosophy, Myenteric plexus, Chemistry, Research and development, Hallucination, Rare disease, Amgen, ACAD, FDA, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development.
  • Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
  • “Liz is a preeminent drug research and development leader with extensive experience in the advancement and commercialization of first in class therapies,” said Steve Davis, Chief Executive Officer.
  • She joined Horizon in 2018 and served in roles of increasing responsibility that culminated at Executive Vice President, Research and Development.

Prilenia Names Jina Swartz, M.D. Ph.D., as Chief Medical Officer

Retrieved on: 
Wednesday, April 3, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, United States of Europe, European Brain Council, DSM-IV codes, ALS, University, Huntington's disease, Merck, Fellow, Therapy, CMO, Multimedia, HD, Pharmaceutical industry

Ph.D., as its first Chief Medical Officer (CMO).

Key Points: 
  • Ph.D., as its first Chief Medical Officer (CMO).
  • In this role, Jina will lead all clinical development and medical affairs activities at Prilenia.
  • Ph.D., Chief Medical Officer at Prilenia (Photo: Business Wire)
    Jina has more than 30 years’ experience in both academic neurology practice and in global drug development at leading pharmaceutical companies and joins Prilenia from Exciva, a neurodegeneration-focused biotech, where she was Chief Medical Officer.
  • Ph.D., Chief Medical Officer of Prilenia.

Garnett Station Partners Launches Accident Care Alliance, a Specialized Accident Injury Healthcare Services Platform

Retrieved on: 
Tuesday, April 2, 2024
Automotive, Physical Therapy, Professional Services, Managed Care, Other Health, Health, General Health, Neurology, Other Automotive, Asset Management, Telemedicine, Virtual Medicine, Pain management, Chiropractic, Patient, Garnett station, Accident, TBI, ACA, Elective surgery, Health insurance

Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.

Key Points: 
  • Garnett Station Partners (“Garnett Station”), a New York-based principal investment firm that manages over $2.3 billion of assets, today announced the launch of Accident Care Alliance (“ACA”), a highly specialized platform comprised of best-in-class healthcare providers focused on delivering holistic, individualized care for those injured primarily in automobile accidents.
  • ACA partners with and grows industry-leading healthcare providers that support an underserved population of individuals injured in automobile accidents and are in need of adequate access to timely, premium healthcare services.
  • “We are building ACA around delivering convenient access and exceptional services to patients who lack access to best-in-class treatment options.
  • Rafi Haramati, Principal at Garnett Station, added, “The accident injury healthcare market is highly fragmented and growing, and with over half of accident injury cases in the United States resulting from automobile accidents, we see a great opportunity to build the leading platform to help improve the services available to injured patients.

Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Health, Neurology, Clinical Trials, Central nervous system, Biology, CNS, Conference, Therapy

Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:45 p.m.

Key Points: 
  • Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:45 p.m.
  • ET.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Retrieved on: 
Monday, April 1, 2024
Health, Neurology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, SVB Securities, Bankruptcy, Neurotoxin, Multiple sclerosis, Patient, King & Spalding, Merz, Sale, Perella Weinberg Partners, LLP, Security (finance), United States bankruptcy court, Morgan Stanley, Ernst & Young, DSM-IV codes, Therapy, Acorda Therapeutics

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) (“Acorda” or “the Company”) today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million.
  • Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, headquartered in Frankfurt am Main, Germany.
  • The decision to file for Chapter 11 protection follows a lengthy strategic review during which the Company explored a wide range of strategic options.
  • Upon court approval, Acorda expects to minimize the impact of the bankruptcy process on its employees, customers, patients, and other key stakeholders.

GE HealthCare closes MIM Software acquisition, bolstering its portfolio and advancing its precision care strategy

Retrieved on: 
Monday, April 1, 2024
Technology, Health, Other Health, Radiology, Oncology, Other Technology, Practice Management, Medical Devices, Software, Managed Care, General Health, Health Technology, Hardware, Data Management, Neurology, Automation, Diagnosis, Cardiology, Molecular imaging, American Urological Association, MRI, Prostate cancer, Nuclear medicine, SNMMI, Patient, PET, Radiation, Cancer, Society, Adjustment, Radiation therapy, Workflow, Radiopharmaceutical, GE HealthCare, SPECT, MIM, Brachytherapy, ASCO, European Association of Urology, Hand, Medical imaging

The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.

Key Points: 
  • The availability of these offerings – including the MIM SurePlan and MIM Symphony families, MIM Maestro, MIM Encore, and more – is in alignment with GE HealthCare’s precision care strategy, which aims to deliver innovative digital solutions across care pathways for more precise, connected, and efficient care across disease states.
  • "We are thrilled to welcome MIM Software, known for driving innovation in multimodal image analytics and workflow, to our global GE HealthCare team,” said Peter Arduini, President & CEO, GE HealthCare.
  • “These new capabilities align with our precision care strategy to personalize care, enhance hospital efficiency and clinician effectiveness, and appeal to new and existing GE HealthCare and MIM Software users who see this as an opportunity to better serve patients and help improve outcomes."
  • “Today marks an exciting new chapter for our team and technology,” adds Andy Nelson, CEO, MIM Software at GE HealthCare.

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Retrieved on: 
Tuesday, April 2, 2024
Science, Neurology, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Growth, PD, Patient, Merz, Sale, Acquisition, Sclerosis, Parkinson's disease, DSM-IV codes, Therapy, Acorda Therapeutics, Physician, Pharmaceutical industry

Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.

Key Points: 
  • Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics.
  • Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
  • This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration.
  • As a German-based but global company, we are very interested in innovative acquisitions, on a global scale," concludes Jörg Bergler.